Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Sickle Cell Disease Gene Therapies Exagamglogene Autotemcel (Casgevy) and Lovotibeglogene Autotemcel (Lyfgenia)

Last updated on

Sickle cell disease gene therapies are a covered benefit for Texas Medicaid clients. Below is more information on these gene therapies:

  • Casgevy (exagamglogene autotemcel) is an autologous genome-edited hematopoietic stem cell-based gene therapy indicated for the treatment of clients 12 years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises or transfusion-dependent ß-thalassemia.
  • Lyfgenia (lovotibeglogene autotemcel) is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of clients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.

Coverage determinations are made on a case-by-case basis. Prior authorization criteria will be included in a future update of the Texas Medicaid Provider Procedures Manual (TMPPM).

Providers should call the TMHP Contact Center at 800-925-9126 with any questions related to prior authorization for fee-for-service clients. Providers should contact managed care organizations for managed care clients.